Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Goodwill (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Goodwill for 16 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Goodwill rose 13.04% to $8.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.1 million, a 13.04% increase, with the full-year FY2025 number at $8.1 million, up 13.04% from a year prior.
  • Goodwill was $8.1 million for Q4 2025 at Anika Therapeutics, roughly flat from $8.1 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $8.1 million in Q2 2021 to a low of $6.7 million in Q3 2022.
  • A 5-year average of $7.6 million and a median of $7.5 million in 2023 define the central range for Goodwill.
  • Peak YoY movement for Goodwill: crashed 76.2% in 2021, then rose 13.04% in 2025.
  • Anika Therapeutics' Goodwill stood at $7.8 million in 2021, then fell by 5.68% to $7.3 million in 2022, then increased by 3.16% to $7.6 million in 2023, then decreased by 5.89% to $7.1 million in 2024, then rose by 13.04% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Goodwill are $8.1 million (Q4 2025), $8.1 million (Q3 2025), and $8.1 million (Q2 2025).